You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

260 Results
Chercheur, Cancer Screening – Program Design, Soins aigus et hospitaliers, Santé Ontario Spécialiste des sciences du comportementdiego.llovet@...
Drug
Other Name(s): Imfinzi®
Apr 2024
Drug
Other Name(s): Sprycel®
Feb 2025
Drug
Other Name(s): Firmagon®
Feb 2025
Drug
Other Name(s): Inqovi®
Feb 2025
Drug
Other Name(s): Jemperli
Feb 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Intent: Palliative
Funding:
Exceptional Access Program
    daSAtinib - Ph+ CML in the chronic phase, with specific criteria
Exceptional Access Program
    daSAtinib - Accelerated phase or blast phase Ph+ CML with documented resistance or intolerance to imatinib, with specific criteria
Feb 2025
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Adjuvant, Palliative
Funding:
ODB - General Benefit
    degarelix
Feb 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    daSAtinib - PH+ ALL, with specific criteria
Feb 2025
Le test de dépistage du cancer du col de l’utérus recherche les types de virus du papillome humain (VPH) qui peuvent parfois provoquer un cancer du...

Pages